Published in Endocr Relat Cancer on June 01, 2005
Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer (2007) 1.63
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer (2008) 1.50
Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer (2008) 1.48
A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods (2015) 1.43
Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One (2011) 1.37
MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med (2006) 1.33
STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel) (2014) 1.29
Inflammation and cancer. World J Gastrointest Surg (2012) 1.12
Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One (2012) 1.00
Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res (2008) 0.99
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis (2011) 0.95
Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. Int J Breast Cancer (2012) 0.92
Fibronectin-alpha4beta1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury. Am J Pathol (2007) 0.91
Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2006) 0.89
Far beyond the usual biomarkers in breast cancer: a review. J Cancer (2014) 0.87
Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol (2010) 0.87
Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Onco Targets Ther (2016) 0.85
Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol (2009) 0.85
Chitosan-based thermoreversible hydrogel as an in vitro tumor microenvironment for testing breast cancer therapies. Mol Pharm (2014) 0.81
TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2. PLoS One (2015) 0.81
Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer. J Cancer Res Clin Oncol (2010) 0.81
Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas. Int J Clin Oncol (2012) 0.80
TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs. Blood (2011) 0.79
Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer (2010) 0.79
Using a cell line breast cancer progression system to identify biomarker candidates. J Proteomics (2013) 0.79
Construction of eukaryotic plasmid expressing human TGFBI and its influence on human corneal epithelial cells. Int J Ophthalmol (2012) 0.78
Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer. Dig Dis Sci (2012) 0.78
Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer. World J Urol (2010) 0.76
RA-XII inhibits tumour growth and metastasis in breast tumour-bearing mice via reducing cell adhesion and invasion and promoting matrix degradation. Sci Rep (2015) 0.76
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC Cancer (2014) 0.75
Anti-cancer effect of Annona Muricata Linn Leaves Crude Extract (AMCE) on breast cancer cell line. BMC Complement Altern Med (2016) 0.75
Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinoma. Bosn J Basic Med Sci (2009) 0.75
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol (1992) 2.91
Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol (2001) 2.68
Tamoxifen in advanced breast cancer. Cancer Treat Rev (1978) 2.53
Duodenal adenomatosis in familial adenomatous polyposis. Gut (2004) 2.38
Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry (1983) 2.32
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol (1999) 1.86
Risk of recurrence 5 years or more after primary Lichtenstein mesh and sutured inguinal hernia repair. Br J Surg (2007) 1.82
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer (2005) 1.68
A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry (1990) 1.68
Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem (1998) 1.65
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg (2003) 1.61
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol (2000) 1.58
Serum YKL-40 and colorectal cancer. Br J Cancer (1999) 1.57
Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry (1983) 1.56
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. Eur J Cancer (1999) 1.55
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol (2011) 1.49
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol (2000) 1.48
Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res (1989) 1.48
Lactational competence and involution of the mouse mammary gland require plasminogen. Development (2000) 1.48
Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group. Br J Surg (2000) 1.47
Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer (2002) 1.47
Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg (2002) 1.41
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Long-term storage of samples for flow cytometric DNA analysis. Cytometry (1983) 1.36
Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res (1999) 1.32
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res (2000) 1.31
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
A precise and efficient stereological method for determining murine lung metastasis volumes. Am J Pathol (2001) 1.28
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res (2000) 1.27
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis (1996) 1.27
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol (2009) 1.26
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem (1997) 1.26
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer (1999) 1.24
Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol (1993) 1.23
Syncytin is involved in breast cancer-endothelial cell fusions. Cell Mol Life Sci (2006) 1.22
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res (1993) 1.22
Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer (1994) 1.22
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res (1995) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Postoperative medical complications are the main cause of early death after emergency surgery for colonic cancer. Br J Surg (2008) 1.18
Detergent and proteolytic enzyme-based techniques for nuclear isolation and DNA content analysis. Methods Cell Biol (1994) 1.17
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis (1999) 1.15
Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion (1999) 1.14
Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat (2000) 1.12
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest (1999) 1.10
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer (2003) 1.08
Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun (2007) 1.08
Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest (2002) 1.07
DNA ploidy-characteristics of human malignant melanoma analysed by flow cytometry and compared with histology and clinical course. Virchows Arch B Cell Pathol Incl Mol Pathol (1983) 1.07
JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways. Cell Death Differ (2004) 1.06
Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening. Br J Cancer (1994) 1.05
Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res (1980) 1.05
Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif (2000) 1.04
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer (1994) 1.04
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol (1989) 1.03
Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis (1997) 1.03
TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer (2006) 1.02
Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. Int J Cancer (1999) 1.02
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat (1995) 1.01
Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ (1998) 1.01
Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based on 253 cases. Cancer (1986) 1.01
A comparison of mathematical methods for the analysis of DNA histograms obtained by flow cytometry. Cell Tissue Kinet (1982) 1.00
The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis (1993) 0.99
Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat (1993) 0.99
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers (2002) 0.99
Influence of major surgery on the mannan-binding lectin pathway of innate immunity. Clin Exp Immunol (2006) 0.99
Intra-operative perforation is an important predictor of local recurrence and impaired survival after abdominoperineal resection for rectal cancer. Colorectal Dis (2011) 0.97
Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl (1994) 0.97
Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. Clin Exp Metastasis (1998) 0.97
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer (1996) 0.97
Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion (1996) 0.96
Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler (1995) 0.96
Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer (1998) 0.96
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol (2001) 0.95